“Genetically, disease progression is associated with the acquisition of further chromosomal aberrations or mutations,” wrote study authors led by Mirle Schemionek, PhD, of University Hospital RWTH Aachen in Germany. “At the epigenetic level, DNA promoter methylation of specific genes, often tumor suppressors, has been associated with disease progression.”

University of Alabama at Birmingham researchers have found a marker on blood cells that may help the most pressing problem in chronic myelogenous leukemia, or CML, today — an inability to get patients off treatment.

Five-year results of the randomised phase III ENESTnd trial show a positive risk-benefit profile for nilotinib in patients with chronic myeloid leukaemia (CML) in chronic phase (CP), as compared to imatinib. Cardiovascular risk does seem to be slightly raised with nilotinib, but improvements in CML disease control likely outweigh those risks. -

Abstract

As a member of the Blood Cancers Alliance (BCA), an informal coalition of charities representing the blood cancer community, Myeloma UK wrote an open letter to The Times newspaper on the Cancer Drugs Fund and the removal of blood cancer drugs from the list. 

The International CML Foundation (iCMLf) is a Foundation established by a group of leading hematologists with a strong interest in CML. The mission of the iCMLf is to improve the outcomes for patients with CML globally. The Foundation is registered as a charitable organisation in England and Wales but its charter is global. Its aims are to foster and coordinate global clinical and research collaborations and to improve clinical practice and disease monitoring in CML, especially in emerging economic regions.

 https://www.dropbox.com/s/twrzp76lcbu7qny/ASH%20CML%20report%202015.pdf?dl=0

Chronic Myeloid Leukemia: Therapy
Program: Oral and Poster Abstracts
Type: Oral